urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
Company profile
Ticker
URGN
Exchange
Website
CEO
Elizabeth Barrett
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Urogen Pharma, Inc. ...
URGN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
14 Mar 24
8-K
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
14 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Regulation FD Disclosure
1 Mar 24
8-K
Regulation FD Disclosure
7 Feb 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
UPLOAD
Letter from SEC
5 Dec 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
Transcripts
URGN
Earnings call transcript
2023 Q4
14 Mar 24
URGN
Earnings call transcript
2023 Q3
14 Nov 23
URGN
Earnings call transcript
2023 Q2
10 Aug 23
URGN
Earnings call transcript
2023 Q1
11 May 23
URGN
Earnings call transcript
2022 Q4
16 Mar 23
URGN
Earnings call transcript
2022 Q3
10 Nov 22
URGN
Earnings call transcript
2022 Q2
11 Aug 22
URGN
Earnings call transcript
2022 Q1
10 May 22
URGN
Earnings call transcript
2021 Q4
21 Mar 22
URGN
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
4
Mark Schoenberg
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
SC 13D/A
Arkin Moshe
22 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
MENORA MIVTACHIM HOLDINGS LTD.
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
4/A
Dong Kim
12 Feb 24
4/A
Dong Kim
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 120.12 mm | 120.12 mm | 120.12 mm | 120.12 mm | 120.12 mm | 120.12 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.30 mm | 8.70 mm | 5.77 mm | 7.09 mm |
Cash used (since last report) | n/a | n/a | 49.89 mm | 59.45 mm | 39.43 mm | 48.51 mm |
Cash remaining | n/a | n/a | 70.24 mm | 60.67 mm | 80.69 mm | 71.61 mm |
Runway (months of cash) | n/a | n/a | 9.6 | 7.0 | 14.0 | 10.1 |
Institutional ownership, Q3 2023
56.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 102 |
Opened positions | 25 |
Closed positions | 8 |
Increased positions | 35 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 222.77 bn |
Total shares | 19.27 mm |
Total puts | 26.60 k |
Total calls | 43.20 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Great Point Partners | 2.62 mm | $36.71 bn |
Menora Mivtachim | 2.30 mm | $32.27 bn |
Monograph Capital Holdings Advisors | 1.57 mm | $14.17 mm |
Ra Capital Management | 1.48 mm | $20.79 bn |
BLK Blackrock | 1.20 mm | $16.78 bn |
Credit Suisse | 1.06 mm | $14.85 bn |
Harel Insurance Investments & Financial Services | 870.19 k | $12.19 mm |
RTW Investments | 857.46 k | $12.01 bn |
Migdal Insurance & Financial | 648.30 k | $9.08 mm |
Silverarc Capital Management | 508.88 k | $7.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Mark Schoenberg | Ordinary Shares | Sell | Dispose S | No | No | 14.05 | 12,000 | 168.60 k | 139,437 |
31 Jan 24 | Mark Schoenberg | Ordinary Shares | Sell | Dispose S | No | No | 15.74 | 1,894 | 29.81 k | 151,437 |
31 Jan 24 | Mark Schoenberg | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 3,333 | 0.00 | 153,331 |
31 Jan 24 | Mark Schoenberg | Ordinary Shares | Sell | Dispose S | No | No | 15.74 | 758 | 11.93 k | 149,998 |
31 Jan 24 | Mark Schoenberg | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 1,333 | 0.00 | 150,756 |
31 Jan 24 | Mark Schoenberg | Ordinary Shares | Sell | Dispose S | No | No | 15.74 | 1,137 | 17.90 k | 149,423 |
31 Jan 24 | Mark Schoenberg | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 2,000 | 0.00 | 150,560 |
31 Jan 24 | Mark Schoenberg | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 10,000 |
31 Jan 24 | Mark Schoenberg | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 3,333 | 0.00 | 6,667 |
31 Jan 24 | Mark Schoenberg | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 1,333 | 0.00 | 1,334 |
News
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
18 Apr 24
UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
15 Apr 24
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
4 Apr 24
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals Alleging Infringement Of US Patent Numbers 9,040,074 And 9,950,069
3 Apr 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
Press releases
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
17 Apr 24
NorthStar Appoints Peter Pfreundschuh to Board of Managers
15 Apr 24
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
15 Apr 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
14 Mar 24
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24